Aggregate Biotech Firms' Financing, Private Equity and the Cyclical Effect: An International Pre-Crisis Baseline (1997–2008)[Financement agrégé des entreprises biotechnologiques, capital-investissement et effet conjoncturel : une référence internationale pré-crise (1997-2008)]

This paper analyses the aggregate financing of biotech firms in an international comparison. We focus on three dimensions: sectoral development indicators (number of listed and unlisted biotech firms, alliances, patents, R&D intensity), private-equity and venture-capital availability, and the cyclical effect of the 2000 stock-market crash. Using OECD, UNU-MERIT and Datastream/Thomson Financial data over 1997–2008 across sixteen developed economies, complemented by a firm-level dynamic panel for R&D intensity, we test four hypotheses on the US-versus-non-US gap in aggregate biotech dynamism and financing, on the cyclical sensitivity of aggregate biotech funding, and on the firm-level cyclical effect on R&D. Three results stand out. First, the United States systematically dominate the non-US sample in sectoral development metrics and in private-equity supply. Second, the aggregate biotech-financing channels — private-equity raised, venture-capital deployed, IPO activity — do not exhibit a clear cyclical break around 2000, supporting a structural-resilience reading of aggregate biotech financing. Third, the firm-level dynamic panel does reveal a positive period-1 effect on R&D intensity. Taken together with the firm-level evidence reported in Tendil (2026a, 2026b), these results suggest that aggregate biotech financing and firm-level financing constraints respond to cyclical shocks through different channels. The findings should be read as a pre-crisis baseline against which post-2008 evidence on biotech IPOs, SPACs, Asian biotech venues and AI-driven discovery firms can be measured.